Research graph
References from Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, evaluated with and without tetanus-reduced diphtheria-acellular pertussis vaccine in healthy children aged 6–17 years: a randomised, active-controlled and placebo-controlled, phase 2b trial. Local targets link to admitted publications; unresolved targets remain external evidence.
Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023
10.1016/s0140-6736(25)01037-2 · 2025 · External reference
Pertussis before, during, and after Covid-19
10.1038/s44321-025-00199-2 · 2025 · External reference
Pertussis prevention: reasons for resurgence, and differences in the current acellular pertussis vaccines
10.3389/fimmu.2019.01344 · 2019 · External reference
Estimating the duration of pertussis immunity using epidemiological signatures
10.1371/journal.ppat.1000647 · 2009 · External reference
Live attenuated B pertussis as a single-dose nasal vaccine against whooping cough
10.1371/journal.ppat.0020065 · 2006 · External reference
Early protection against pertussis induced by live attenuated Bordetella pertussis BPZE1 depends on TLR4
10.4049/jimmunol.1901102 · 2019 · External reference
Long-term immunity against pertussis induced by a single nasal administration of live attenuated B pertussis BPZE1
10.1016/j.vaccine.2010.08.017 · 2010 · External reference
A live attenuated Bordetella pertussis candidate vaccine does not cause disseminating infection in gamma interferon receptor knockout mice
10.1128/cvi.00082-09 · 2009 · External reference
IL-17-dependent SIgA-mediated protection against nasal Bordetella pertussis infection by live attenuated BPZE1 vaccine
10.1038/s41385-018-0073-9 · 2018 · External reference
Live attenuated pertussis vaccine BPZE1 protects baboons against Bordetella pertussis disease and infection
10.1093/infdis/jix254 · 2017 · External reference
A phase I clinical study of a live attenuated Bordetella pertussis vaccine—BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers
10.1371/journal.pone.0083449 · 2014 · External reference
Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study
10.1016/s1473-3099(20)30274-7 · 2020 · External reference
Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans
10.1172/jci135020 · 2020 · External reference
Safety and immunogenicity of live, attenuated intranasal Bordetella pertussis vaccine (BPZE1) in healthy adults
10.1016/j.vaccine.2022.09.075 · 2022 · External reference
Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus-diphtheria-acellular pertussis vaccine: a randomised, double-blind, phase 2b trial
10.1016/s0140-6736(22)02644-7 · 2023 · External reference
Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis
10.1016/j.lanmic.2025.101211 · 2025 · External reference
Modulation of the infant immune responses by the first pertussis vaccine administrations
10.1016/j.vaccine.2006.06.046 · 2007 · External reference
Antigen-specific responses to diphtheria-tetanus-acellular pertussis vaccine in human infants are initially Th2 polarized
10.1128/iai.68.7.3873-3877.2000 · 2000 · External reference
Development of high-throughput serum bactericidal assays for Bordetella pertussis to evaluate BPZE1
10.3390/vaccines14060492 · 2026 · External reference
Correlates of protection induced by vaccination
10.1128/cvi.00131-10 · 2010 · External reference
BPZE1 vaccination induces IL-17+ and IL-22+ CD4+ T cells associated with nasal mucosal secretory IgA responses in humans: effects on virulent Bordetella pertussis colonisation
10.1038/s41541-026-01443-7 · 2026 · External reference
Characterization of antibody inhibiting adherence of Bordetella pertussis to human respiratory epithelial cells
10.1128/jcm.20.2.167-170.1984 · 1984 · External reference
Bordetella pertussis attachment to respiratory epithelial cells can be impaired by fimbriae-specific antibodies
10.1111/j.1574-695x.2005.00001.x · 2006 · External reference
Immunoglobulin A-mediated protection against Bordetella pertussis infection
10.1128/iai.69.8.4846-4850.2001 · 2001 · External reference
Vaccine-induced Th17 cells are established as resident memory cells in the lung and promote local IgA responses
10.1038/mi.2016.28 · 2017 · External reference
Cutting edge: lung mucosal Th17-mediated responses induce polymeric Ig receptor expression by the airway epithelium and elevate secretory IgA levels
10.4049/jimmunol.0900237 · 2009 · External reference
Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis
10.1016/s0264-410x(98)00227-8 · 1998 · External reference
Global spatial dynamics and vaccine-induced fitness changes of Bordetella pertussis
10.1126/scitranslmed.abn3253 · 2022 · External reference
Next-generation pertussis vaccines based on the induction of protective T cells in the respiratory tract
10.3390/vaccines8040621 · 2020 · External reference
IL-17 and IFN-g-producing respiratory tissue-resident memory CD4 T cells persist for decades in adults immunized as children with whole-cell pertussis vaccines
10.1093/infdis/jiae034 · 2024 · External reference
Complete genome sequences of Bordetella pertussis isolates B1917 and B1920, representing two predominant global lineages
10.1128/genomea.01301-14 · 2014 · External reference
Acellular pertussis vaccines induce anti-pertactin bactericidal antibodies which drives the emergence of pertactin-negative strains
10.3389/fmicb.2020.02108 · 2020 · External reference
